Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study

Area of Science:

• Hematology
• Pediatric Oncology
• Genetics

Background:

• Transient myeloproliferative disorder (TMD) affects 5-10% of children with Down syndrome (DS).
• TMD carries significant risks, including early death (20%) and progression to myeloid leukemia (ML-DS) in 20-30% of cases.
• Effective interventions for TMD are crucial to improve outcomes in DS patients.

Purpose of the Study:

• To evaluate the impact of low-dose cytarabine on survival and prevention of ML-DS in pediatric patients with TMD.
• To assess the efficacy of cytarabine in reducing TMD-related mortality and disease progression.
• To compare outcomes in treated patients with a historical control group.

Main Methods:

• A multicenter, nonrandomized, historically controlled trial (TMD Prevention 2007) involving 102 patients with TMD.
• Cytarabine (1.5 mg/kg for 7 days) administered to symptomatic patients or those with minimal residual disease (MRD) at 8 weeks.
• Comparison of cumulative incidence of early death and ML-DS with historical controls.

Main Results:

• Overall survival at 5 years was 91 ± 3% for enrolled TMD patients.
• Symptomatic patients receiving cytarabine showed a significantly lower cumulative incidence of early death compared to historical controls (12 ± 5% vs 33 ± 7%, P=0.02).
• Low-dose cytarabine did not significantly reduce the cumulative incidence of ML-DS compared to controls (25 ± 7% vs 14 ± 7%, P=0.34).

Conclusions:

• Low-dose cytarabine treatment can effectively reduce TMD-related mortality in children with Down syndrome.
• The current treatment regimen is insufficient to prevent the progression of TMD to myeloid leukemia (ML-DS).
• Further research is needed to identify strategies that can prevent ML-DS in this vulnerable pediatric population.